This company listing is no longer active
LBPH Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Longboard Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.98 |
| 52 Week High | US$60.03 |
| 52 Week Low | US$3.82 |
| Beta | 1.09 |
| 1 Month Change | 0.49% |
| 3 Month Change | 76.36% |
| 1 Year Change | 1,414.65% |
| 3 Year Change | 1,042.48% |
| 5 Year Change | n/a |
| Change since IPO | 260.24% |
Recent News & Updates
Recent updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Oct 15My Strategy For Longboard Pharmaceuticals After Its Big Run
Aug 28We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth
Jul 12
Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely
Mar 16Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?
Oct 03We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate
Dec 25Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth
Sep 10We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely
May 28Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
Feb 11Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation
Oct 27Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Jun 12Longboard Pharmaceuticals EPS beats by $0.29
May 10Shareholder Returns
| LBPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.1% | -1.9% | -1.2% |
| 1Y | 1,414.6% | 1.7% | 23.2% |
Return vs Industry: LBPH exceeded the US Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: LBPH exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| LBPH volatility | |
|---|---|
| LBPH Average Weekly Movement | 17.0% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LBPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LBPH's weekly volatility has decreased from 46% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 50 | Kevin Lind | www.longboardpharma.com |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases.
Longboard Pharmaceuticals, Inc. Fundamentals Summary
| LBPH fundamental statistics | |
|---|---|
| Market cap | US$2.34b |
| Earnings (TTM) | -US$76.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-30.7x
P/E RatioIs LBPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$76.34m |
| Earnings | -US$76.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LBPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/02 13:23 |
| End of Day Share Price | 2024/11/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Longboard Pharmaceuticals, Inc. is covered by 3 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Neena Bitritto-Garg | Citigroup Inc |
| Yatin Suneja | Guggenheim Securities, LLC |